Compumedics Limited · ASX:CMP

Compumedics — Investor Presentation (November 2026)

18 slides from Compumedics's investor presentation, Nov 11, 2026

  1. Slide 1: Realising the value we have built

    COMPUMEDICS LIMITED (ASX: CMP) | INVESTOR UPDATE | NOVEMBER 2026 rsonal use only Realising the value we have built A record FY26, and a new strategy to realise the captive value of our R&D — efficiently, and designed to be accretive for shareholders Dr David Burton Executive Chairman and CEO David L

  2. Slide 2: A global medical technology company built over 39 years

    WHO IS COMPUMEDICS A global medical technology company built over 39 years rsonal use only 25,000+ A$60.3m ~175 1987 Installed systems FY26 revenue People Founded in Melbourne in 60+ countries a record; 61% Asia-Pacific Australia, US, Germany, France, Korea ASX-listed since 2000 Six revenue segments

  3. Slide 3: A new strategy to realise the captive value of our R&D

    VALUE REALISATION PROGRAM A new strategy to realise the captive value of our R&D Each of our growth platforms has globally competitive technology rsonal use only and early commercial scale. What has held back value is the speed Program 1 · Somfit® US pharmacy & Adviser appointed of commercialisation

  4. Slide 4: You told us. Here is what we have done

    WHAT IS DIFFERENT THIS TIME You told us. Here is what we have done rsonal use only You told us (2025 roadshows) What we have done Evidence How will you realise value? Before: deals pursued by management and the Board alongside running the business. Now: Slides 3 and 5; ASX, 6 Nov 2026 five programs,

  5. Slide 5: A deeper team behind the value-realisation program

    LEADERSHIP DEPTH A deeper team behind the value-realisation program rsonal use only Mike Stone Troy Lamb David Lawson Chief Commercial Officer, USA CFO and Company Secretary Finance Director Since June 2026. 20+ years medtech sales leadership From 1 Nov 2026; Deputy CFO since March 2025. 20+ 26 year

  6. Slide 6: FY26: record revenue, a return to profit and much stronger cash

    FY26 RESULT FY26: record revenue, a return to profit and much stronger cash rsonal use only A$60.3m A$5.4m A$0.25m A$6.6m Revenue EBITDA Net profit after tax Operating cash inflow +18.5% on FY25 — a record +74%; margin 9% (FY25: 6%) FY25: loss of A$1.3m FY25: A$0.4m Revenue (A$m) EBITDA (A$m) 5.4 60

  7. Slide 7: More of our revenue now recurs

    QUALITY OF REVENUE More of our revenue now recurs — led by Somfit® and NEXUS 360® Somfit® & NEXUS 360® SaaS revenue (A$m) rsonal use only +70% 10.2 SaaS growth in FY26 17% of Group revenue (FY25: 12%) 6.0 30% Recurring revenue 4.3 A$18.3m: SaaS, consumables and care (FY25: 27%; FY24: 25%) 1,000,000+

  8. Slide 8: We missed our FY26 guidance — and we have changed how we guide

    WHAT WE SAID, WHAT WE DELIVERED We missed our FY26 guidance — and we have changed how we guide rsonal use only FY26 guidance vs result How we will guide from now on Revenue EBITDA • One year ahead only, and conservatively • No multi-year scenarios or valuations Guidance, Oct 2025 – Feb 2026 >A$70m ~

  9. Slide 9: First US shipment of Somfit D — November 2026

    SOMFIT® HOME SLEEP TESTING First US shipment of Somfit® D — November 2026 rsonal use only 75%+ 2 of top 5 Shipping of the Australian and NZ pharmacy home-sleep-testing segment global CROs with Master Services Agreements; approximately A$3.5m of products already invoiced to Somfit® D, our single-use

  10. Slide 10: From 2027, US home sleep tests are paid by how much they measure

    US REIMBURSEMENT FROM 1 JANUARY 2027 From 2027, US home sleep tests are paid by how much they measure rsonal use only Where Somfit® sits • Measures sleep directly from frontal EEG, EOG and High EMG 11+ channels · 9+ parameter categories • Today: current US release designed to support moderate-comple

  11. Slide 11: MEG has moved from promise to revenue — the US is next

    ORIONMEG® LIFESPAN MEG has moved from promise to revenue — the US is next rsonal use only A$9.7m A$13.1m 7 FY26 MEG revenue MEG order book Orion systems sold ~A$30m to date; 3 being installed, 3 more in from nil in FY25 entering FY27 manufacture Why it is different US entry • The only dual adult/pae

  12. Slide 12: DWL: an established specialist business with patented robotic upside

    DWL® CEREBROVASCULAR DIAGNOSTICS DWL®: an established specialist business with patented robotic upside rsonal use only A$4.5m EU-MDR · FDA US · EU · CN FY26 revenue Regulatory clearances Robotic-probe patents FY25: A$4.7m; DWL USA up 58% in US$; orders A$4.7m, EU-MDR across the range; EZ-Dop® FDA 51

  13. Slide 13: A stronger balance sheet; covenants met

    BALANCE SHEET A stronger balance sheet; covenants met rsonal use only A$6.1m A$13.1m A$5.6m Cash Borrowings Cash less invoice facility and overdraft 30 June 2026 (FY25: A$2.7m) Bank of Melbourne, refinanced Mar 2026 improved by A$6.7m Bank covenant Requirement 30 June 2026 No current plans to raise

  14. Slide 14: FY27: another year of profitable growth

    FY27 FY27: another year of profitable growth rsonal use only FY27 guidance: further double-digit revenue growth, with EBITDA growing faster than revenue. Grow Somfit® in the US Deliver the order book Expand MEG into the US Realise R&D value Somfit® D shipping; 2027 A$28.3m of open orders entering US

  15. Slide 15: Why look at Compumedics now — and what to watch

    SUMMARY Why look at Compumedics now — and what to watch rsonal use only What to watch Timing Status Delivered Record FY26; profit and cash turned; clean audit First Somfit® D shipment to the US Nov 2026 Delivered New US unattended sleep-test codes take effect 1 Jan 2027 External Half-year result Feb

  16. Slide 16: Capital structure and register

    CORPORATE SNAPSHOT Capital structure and register rsonal use only 199.8m A$47.9m A$6.1m Shares on issue Market capitalisation Cash ASX, at 10 November 2026 at A$0.24 per share, 10 November 2026 borrowings A$13.1m; 30 June 2026 Register at 17 September 2026 (Annual Report 2026) Aligned with sharehold

  17. Slide 17: Disclaimer

    IMPORTANT INFORMATION Disclaimer rsonal use only This presentation has been prepared by Compumedics Limited (ABN 95 006 854 897) and contains summary information about Compumedics and its activities current as at the date of this presentation. It should be read with Compumedics' other periodic and c

  18. Slide 18: Questions

    rsonal use only Questions Compumedics Limited (ASX: CMP) · 30–40 Flockhart Street, Abbotsford VIC 3067 · www.compumedics.com.au Dr David Burton Executive Chairman and CEO David Lawson Finance Director Troy Lamb Chief Financial Officer and Company Secretary +61 3 8420 7300

Compumedics — Investor Presentation (November 2026) on 6ix